The company is voluntarily recalling all unexpired lots of nitroglycerin products produced at its Houston location for potency issues.
On June 15, 2017, Advanced Pharma, Inc. d/b/a Avella of Houston announced it is voluntarily recalling all unexpired lots of nitroglycerin products produced at its Houston location from March 3, 2017–May 31, 2017 to the hospital level. The recall is in response to potential problems with product potency and is limited to the company’s Houston location.
According to the company, laboratory test results indicated a lower than expected potency on certain lots of nitroglycerin. Advanced Pharma has not received any reports of adverse events as of June 15 but is recalling all unexpired lots out of caution. A reduced dose could interrupt a patient’s treatment, according to the company.
The recalled NitroGlycerin products include the 100 mcg per mL and 200 mcg per mL strengths available in 5 mL, 10 mL, and 20 mL sterile single dose syringes and packaged in various sizes per carton. These products were distributed to healthcare facilities nationwide in the United States between March 9, 2017 to June 1, 2017 and have expiration dates ranging from June 9, 2017 to August 15, 2017.
Customers should return unused product to Avella. Adverse events can be reported to FDA at www.fda.gov/medwatch/report.htm.
Source: FDA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.